Progressive Supranuclear Palsy Therapeutics Market Size, Share, Value, Forecast and outlook (2024-2031)

Global Progressive Supranuclear Palsy Therapeutics Market is segmented By Medication Type (Anti-Parkinsonian Drugs, Anti-Depressants, Botulinumtoxin, Others) By Age Group (Adults, Geriatrics) By Gender (Male, Female) By Distribution Channel (Offline, Online) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Progressive Supranuclear Palsy Therapeutics Market Overview

The global progressive supranuclear palsy therapeutics market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Progresisve supranuclear palsy (PSP) is a rare neurological condition that affects gait, balance, swallowing and movement of a person. Also known as Steele-Richardson-Olszewski syndrome and parkinson-plus disorder, it is caused by damage to the brain cells that control movement and co-ordination of the body, but the exact cause in still unknown.

Current treatment options include symptomatic relief and supportive care, no specific treatment is available in the market that cures the condition. Research is being conducted to bring out novel treatments that focusing on slowing the condition. Rising products developments, increasing prevelance of the condition, rising funding by government agencies are expected to drive the market growth in the forecast period.

Progressive Supranuclear Palsy Therapeutics Market Scope

For more details on this report - Request for Sample

Progressive Supranuclear Palsy Therapeutics Market Dynamics: Drivers

Rising product developments and pipeline drugs

Progresisve supranuclear palsy (PSP) as a rare condition affects very less population globally. According to a systamic study published in the International Parkinson and Movement Disorder Society in may 2022, the pooled prevelance of PSP is 7.1 per 100,000 patients per year. Managing the patient with PSP is quite difficult as it causes motor and cognitive impairment rapidly and their survival rate ranges between 3 to 8 years. 

In the current scenario, the treatment of PSP is completely focused on symptomatic relief and assisted care. As the motor symptoms are the major manifestations in PSP, the treatment for these symptoms can be given by using anti-parkinsonism drugs like levodopa and carbidopa. For cognitive symptoms, there is no accepted treatment that provides promising imporvement in the patient’s cognitive ability. Currently many trials were on-going which focuses on for upbringing disease modifying treatments. 

As Tau protien plays a crucial role in brain cell damage in PSP patients, it has become a center of attraction for developing novel therapies. Some of the trials currently in the last phases, if found promising, may enter into the market in the forecast period and may boost the overall market growth.

For instance, in December 2023, AMYLYX Pharmaceuticals has started phase 3 ORION study of AMX0035 in progressive supranuclear palsy (PSP). This is a global trial being conducted across 100 sites around the world and focusses on evaluating the changes in disease progression. The company aims to finish the trail by mid of 2027. 

This drugs has already been approved for treatment of amyotrophic lateral sclerosis (ALS) in U.S. and Canada. According to DataM analysis, once the trial has been finished successfully, the anticipated market entry is predicted to be in 2029. 

Also, Woolsey Pharmaceuticals, Inc. has initiated phase 2a clinical trials for BRAVYL (fusadil) against 4 taupathies which also include progressive supranuclear palsy. Fusadil is a Rho Kinase (ROCK) Inhibitor which is involved in  the tau protein phosphorylation and aggrevation of its activity. The trial is currently active and provided the last update in June 2022. 

Another drug developed by Transposon Therapeutics, Inc. called “TPN-101” is currently being evaulated in patients with progressive supranuclear palsy which is also in phase-2a trials. This drug aims at blocking LINE-1 expression which was found to be causing neurodegeneration in PSP patients. 

There are several other trials likewise which are active and aiming to treatment PSP. These pipeline drugs once entered into the market, they may revolutionize the treatment strategy of PSP and bring significant difference in the market value of PSP therapeutics. Moreover, the rising prevalance of progessive supranuclear palsy and rising screening programs are expected to further boost the market growth.

Restraints

The treatment of progressive supranuclear palsy primarily focuses on symptomatic relief rather than targeting the underlying cause of the disease. Currently, no disease-modifying therapies are available that may cure the condition, and it is highly unlikely to save end-stage patients with both cognitive and motor failure. Moreover, since the condition is very rare, it presents as an obstacle to research activities and drug development. These are the major factors that restrain the market growth in the forecast period.

Progressive Supranuclear Palsy Therapeutics Market Segment Analysis

The global progressive supranuclear palsy therapeutics market is segmented based on medication type, age group, gender, distribution channel and region.

The anti-parkinsonian drugs in the medication type segment accounted for approximately 72.50% of the Progressive supranuclear palsy therapeutics market share

Till date, no disease modifying therapies are available for progressive supranuclear palsy, the treatment mainly focuses on providing symptomatic relief. Symptoms that are troublesome in PSP patients are motor disbilities such as loss of movement, gait, rigidity, postural instability, bradykinasia etc, resmbling parkinsonism.  Progressive supranuclear palsy also known as atypical parkinsons disease, can be treated by using the mainstay treatments for parkinsons disease such as dompamine replacement therapy. 

In this dompanine replacement therapy, dopamine analogues such as levodopa, carbidopa were administered which are known to alleviate the motor symptoms. These drugs were found to be beneficial in progressive supranuclear palsy as well due to close resemblance of the condition with parkinsonism. Moreover, another drug called amantidine used in parkinsonism is also found to be helpful in alleviating the motor symptoms in progressive supranuclear palsy patients. 

It is a recommended practice to use these anti-parkinsonian drugs in progressive supranuclear palsy by many physicians all across the world. Although a complete cure cannot be achieved, the motor symptoms can be alleviated in the patient. 

For instance, according to National Institute of Neurology and Stroke, there is no cure currently availalable for progressive supranuclear palsy. The available treatments majorly focus on motor disabilities, and the drugs used for parkinsonism such as levodopa, amantadine are useful for treating these motor diabilites in progressive supranuclear palsy patients. 

In January, 2024 a case reported presented in Elsevier, has stated that the treatment of patient with progressive supranuclear palsy majorly focues on alliviating motor symptoms. The anti-parikinsonian drugs such as levodopa and amantatide provide symptomatic relief in about 50% of the patients. 

Progressive Supranuclear Palsy Therapeutics Market Geographical Analysis

North America accounted for approximately 45.74% of the market share 

North America is dominating the progressive supranuclear palsy therapeutics market due to its well advanced healthcare policies and well equipped healthcare settings that provide appropriate and advanced care for neurodegenerative patients. Moreover, the major countries in the region such as the U.S. and Canada have organizations focusing on creating awareness and providing care plans for neurodegenerative conditons that incudle progressive supranuclear palsy. Also, the research and development activities in the region is higher for neurological conditions as compared to any other high income country in the world. 

For instance, on October 5, 2023, CurePSP a leading non-profit organization in North America which is focused on rising awareness, providing care and cure of progressive supranuclear palsy had announced establishment of three new facilities in the region, making it presence in 33 locations across U.S. and Canada. With this expansion, CurePSP aims to assisst and progress the diagnostics, care, cure and clinical research related to progresisve supranuclear palsy, corticobasal degeneration (CBD) and multiple system atrophy (MSA). Moreover, on March 14, 2024, the organization has announced funding of two projects that focuses on taupathies including progressive supranuclear palsy.

Progressive Supranuclear Palsy Therapeutics Market Competitive Landscape

The major global players in the progressive supranuclear palsy therapeutics market include Amneal Pharmaceuticals LLC., Teva Pharmaceuticals USA, Inc., AbbVie., Supernus Pharmaceuticals, Inc., Novartis AG, Upsher-Smith Laboratories, LLC., Acorda Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd. and Organon group of companies among others. 

Why Purchase the Report?

• To visualize the global progressive supranuclear palsy therapeutics market segmentation based on medication type, age group, gender, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of progressive supranuclear palsy therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global progressive supranuclear palsy therapeutics market report would provide approximately 70 tables, 60 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies